Pharmacokinetics of tablet and liquid formulations of oral 6-mercaptopurine in children with acute lymphoblastic leukemia

[1] Toft N(2018)Results of NOPHO ALL2008 treatment for patients aged 1–45 years with acute lymphoblastic leukemia Leukemia 32 606-615

[2] Birgens H(2015)Acute lymphoblastic leukemia in children N Engl J Med 373 1541-1552

[3] Abrahamsson J(2016)Successful therapy reduction and intensification for childhood acute lymphoblastic leukemia based on minimal residual disease monitoring: study ALL10 from the Dutch Childhood Oncology Group J Clin Oncol 34 2591-2601

[4] Griskevicius L(2012)Acute leukemia incidence and patient survival among children and adults in the United States, 2001–2007 Blood 119 34-43

[5] Hallbook H(2014)Mercaptopurine/Methotrexate maintenance therapy of childhood acute lymphoblastic leukemia: clinical facts and fiction J Pediatr Hematol Oncol 36 503-517

[6] Heyman M(2000)Six months of maintenance chemotherapy after intensified treatment for acute lymphoblastic leukemia of childhood J Clin Oncol 18 1508-1516

[7] Klausen TW(1990)Results and significance of six randomized trials in four consecutive ALL-BFM studies Haematol Blood Transfus 33 439-450

[8] Jonsson OG(2017)DNA-thioguanine nucleotide concentration and relapse-free survival during maintenance therapy of childhood acute lymphoblastic leukaemia (NOPHO ALL2008): a prospective substudy of a phase 3 trial Lancet Oncol 18 515-524

[9] Palk K(2012)Nonadherence to oral mercaptopurine and risk of relapse in Hispanic and non-Hispanic white children with acute lymphoblastic leukemia: a report from the children's oncology group J Clin Oncol 30 2094-2101

[10] Pruunsild K(2017)Long-term outcome of 6-month maintenance chemotherapy for acute lymphoblastic leukemia in children Leukemia 31 580-584

[1] Toft N(2018)Results of NOPHO ALL2008 treatment for patients aged 1–45 years with acute lymphoblastic leukemia Leukemia 32 606-615

[2] Birgens H(2015)Acute lymphoblastic leukemia in children N Engl J Med 373 1541-1552

[3] Abrahamsson J(2016)Successful therapy reduction and intensification for childhood acute lymphoblastic leukemia based on minimal residual disease monitoring: study ALL10 from the Dutch Childhood Oncology Group J Clin Oncol 34 2591-2601

[4] Griskevicius L(2012)Acute leukemia incidence and patient survival among children and adults in the United States, 2001–2007 Blood 119 34-43

[5] Hallbook H(2014)Mercaptopurine/Methotrexate maintenance therapy of childhood acute lymphoblastic leukemia: clinical facts and fiction J Pediatr Hematol Oncol 36 503-517

[6] Heyman M(2000)Six months of maintenance chemotherapy after intensified treatment for acute lymphoblastic leukemia of childhood J Clin Oncol 18 1508-1516

[7] Klausen TW(1990)Results and significance of six randomized trials in four consecutive ALL-BFM studies Haematol Blood Transfus 33 439-450

[8] Jonsson OG(2017)DNA-thioguanine nucleotide concentration and relapse-free survival during maintenance therapy of childhood acute lymphoblastic leukaemia (NOPHO ALL2008): a prospective substudy of a phase 3 trial Lancet Oncol 18 515-524

[9] Palk K(2012)Nonadherence to oral mercaptopurine and risk of relapse in Hispanic and non-Hispanic white children with acute lymphoblastic leukemia: a report from the children's oncology group J Clin Oncol 30 2094-2101

[10] Pruunsild K(2017)Long-term outcome of 6-month maintenance chemotherapy for acute lymphoblastic leukemia in children Leukemia 31 580-584